• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

    36.80 +0.73 (+2.02%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 670,641
    Open 36.18
    Bid (Size) 29.14 (200)
    Ask (Size) 37.97 (100)
    Prev. Close 36.07
    Today's Range 35.82 - 37.88
    52wk Range 12.73 - 37.88
    Shares Outstanding 36,130,121
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares? ↗
    Focused on innovative cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares? ↗
    Focused on urinary tract cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    +62.0%
    +62.0%
    1 Month
    +36.1%
    +36.1%
    3 Month
    +104.7%
    +104.7%
    6 Month
    +58.8%
    +58.8%
    1 Year
    +168.6%
    +168.6%

    More News

    Read More
    UROGEN PHARMA LTD (NASDAQ:URGN) Flawlessly Passes Minervini Trend Template with Accelerating Growth ↗
    Via Chartmill
    News headline image
    UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    UroGen Pharma (NASDAQ:URGN) Crushes Q1 Estimates as ZUSDURI Momentum Accelerates ↗
    Via Chartmill
    UROGEN PHARMA LTD (NASDAQ:URGN) Reports Mixed Q4 2025 Results Amid Strong Commercial Progress ↗
    Via Chartmill
    News headline image
    UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
    Via The Motley Fool
    News headline image
    UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen (URGN) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    UroGen Pharma to Present at Upcoming Investor Conferences
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗
    Via The Motley Fool
    News headline image
    This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain ↗
    Via The Motley Fool
    News headline image
    Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen (URGN) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings

    Frequently Asked Questions

    Is UroGen Pharma Ltd. - Ordinary Shares publicly traded?
    Yes, UroGen Pharma Ltd. - Ordinary Shares is publicly traded.
    What exchange does UroGen Pharma Ltd. - Ordinary Shares trade on?
    UroGen Pharma Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for UroGen Pharma Ltd. - Ordinary Shares?
    The ticker symbol for UroGen Pharma Ltd. - Ordinary Shares is URGN on the Nasdaq Stock Market
    What is the current price of UroGen Pharma Ltd. - Ordinary Shares?
    The current price of UroGen Pharma Ltd. - Ordinary Shares is 36.80
    When was UroGen Pharma Ltd. - Ordinary Shares last traded?
    The last trade of UroGen Pharma Ltd. - Ordinary Shares was at 06/30/26 04:00 PM ET
    What is the market capitalization of UroGen Pharma Ltd. - Ordinary Shares?
    The market capitalization of UroGen Pharma Ltd. - Ordinary Shares is 1.33B
    How many shares of UroGen Pharma Ltd. - Ordinary Shares are outstanding?
    UroGen Pharma Ltd. - Ordinary Shares has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.